- Home
- JBLU vs IBRX Comparison
JBLU vs IBRX Comparison
Compare JBLU & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- IBRX
- Stock Information
- Founded
- JBLU 1998
- IBRX 2014
- Country
- JBLU United States
- IBRX United States
- Employees
- JBLU N/A
- IBRX N/A
- Industry
- JBLU Air Freight/Delivery Services
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JBLU Consumer Discretionary
- IBRX Health Care
- Exchange
- JBLU Nasdaq
- IBRX Nasdaq
- Market Cap
- JBLU 2.1B
- IBRX 2.4B
- IPO Year
- JBLU N/A
- IBRX N/A
- Fundamental
- Price
- JBLU $3.67
- IBRX $2.47
- Analyst Decision
- JBLU Sell
- IBRX Strong Buy
- Analyst Count
- JBLU 12
- IBRX 5
- Target Price
- JBLU $5.00
- IBRX $11.35
- AVG Volume (30 Days)
- JBLU 30.6M
- IBRX 8.0M
- Earning Date
- JBLU 04-22-2025
- IBRX 05-08-2025
- Dividend Yield
- JBLU N/A
- IBRX N/A
- EPS Growth
- JBLU N/A
- IBRX N/A
- EPS
- JBLU N/A
- IBRX N/A
- Revenue
- JBLU $9,279,000,000.00
- IBRX $14,745,000.00
- Revenue This Year
- JBLU $6.12
- IBRX $621.53
- Revenue Next Year
- JBLU $6.33
- IBRX $163.57
- P/E Ratio
- JBLU N/A
- IBRX N/A
- Revenue Growth
- JBLU N/A
- IBRX 2270.58
- 52 Week Low
- JBLU $3.34
- IBRX $2.28
- 52 Week High
- JBLU $8.31
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- JBLU 35.05
- IBRX 41.67
- Support Level
- JBLU $3.34
- IBRX $2.35
- Resistance Level
- JBLU $3.81
- IBRX $3.04
- Average True Range (ATR)
- JBLU 0.43
- IBRX 0.28
- MACD
- JBLU -0.03
- IBRX -0.02
- Stochastic Oscillator
- JBLU 19.08
- IBRX 13.19
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The operating segments of company are Domestic & Canada, Caribbean & Latin America and Atlantic. Majority of revenue is generated from Domestic & Canada segment.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.